🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to the new members of our #RadOnc family here at Moffitt Cancer Center 🫶🏽🔥

Congratulations!

Thrilled you are joining us! Moffitt Cancer Center Jessica Frakes Kosj Yamoah MD, PhD

Welcome to Moffitt!

Received this letter today. Extremely honored to join this laser-focused group of clinicians/scientists/advocates that work tirelessly to eradicate #bladdercancer. Much to learn & much to do for our patients. Thank you IBCG for the opportunity.

🎙️ In honor of #HeadandNeckCancerAwarenessMonth, we’re spotlighting a new podcast episode of On Target: Logistics of Radiation Therapy in the Treatment of Head & Neck Cancers. 🎧 Listen now: astro.org/podcasts Niema Razavian, MD Edina Wang ASTRO Support For People With Oral, Head And Neck Cancer Head and Neck Cancer Alliance

Grateful for the opportunity to work with this amazing team trying to find more treatment options for patients with recurrent high-grade gliomas!🧠 Moffitt Cancer Center MoffittRadOnc Editor - Neuro-Oncology Advances SNO doi.org/10.1093/noajnl…

Great to be speaking at MRinRT conference with great physicians, physicists and colleagues ! Phenomenal work being done! Moffitt Cancer Center MoffittRadOnc #radonc

#FollowFriday Meet Stephen Rosenberg, MD (Stephen Rosenberg, MD), a thoracic oncologist in the radiation department and the Director of Adaptive Radiotherapy. His clinical focus is the treatment of thoracic malignancies, and his research explores the combination of radiation therapy with

Key points of the article: - #Hypofractionated stereotactic #ReIrradiation in combination with nivolumab, ipilimumab, and bevacizumab in patients with recurrent bevacizumab-naïve #HighGradeGlioma is safe. - The median overall survival was 15.6 months bit.ly/3GbAIwO

Congrats, Dr. Upadhyay! MoffittRadOnc

Results from our Ph II multi-institutional study now out in IJROBP - The Red Journal redjournal.org/article/S0360-… Overall & objective responses noted in PD-L1 neg metastatic cervical ca with use of SBRT and atezo. Collaboration between MoffittRadOnc MoffittGYNONC OhioStateRadOnc 🤝 OncoAlert

From #ASCO25: Kamran Ahmed, MD (Kamran Ahmed) highlights results from a phase II trial of SBRT + atezolizumab in metastatic cervical cancer, showing promising responses even in PD-L1 negative tumors. #MoffittASCO25

Critical question for C-POST. Without an OS benefit (and no real space between the curves currently), should cemiplimab be reserved for salvage?

Congratulations to our graduating chief residents for passing their clinical boards!! 🎉💯 JM Bryant, MD Ruben J. Cruz, MD

A multi-institutional phase II trial revealed SBRT and atezolizumab was well tolerated in stage IV cervical cancer with responses in PD-L1 negative tumors. Read it in the #RedJournal. Kamran Ahmed Robert Wenham MoffittRadOnc @MoffittGynOnc #radonc tinyurl.com/redahmed

Moffitt GME Graduation - 46 graduates - congrats to all of you! Good luck and thank you for the years of incredible patient care, ground breaking research and being an integral part of the team. Moffitt Cancer Center

Congratulations to our Graduating Medical and Physics Residents! (Dr. Bryant, Dr. Cruz-Chamorro and Dr. Koo). We are so proud of you and know you will go onto great things! JM Bryant, MD Ruben J. Cruz, MD Jessica Frakes Evan Wuthrick Kosj Yamoah MD, PhD MoffittRadOnc Moffitt Cancer Center #radonc

#hncsm tumor board❓- what is benefit of concurrent adjuvant chemo in pts w minor (<2mm) ENE? In this multi-inst RR, adjuvant chemo: 🔘 ❌ ⬆️ LRC, DFS, OS for Minor ENE 🔘 ✅ ⬆️ DFS, OS for Major ENE 🔘 ☢️ #radonc ⬆️ DFS for Minor ENE ja.ma/4kMfcOB

Rising PGY-5s and anyone interested, we have a 5th HN rad onc position Moffitt Cancer Center. If interested in joining a busy team, including me, Dr. M Echevarria, George Q. Yang, MD, and Niema Razavian, MD, reach out and can chat about the position.